The Truth About Eggs & Cholesterol with Tom Dayspring, MD

Summary

Tom Dayspring, MD, discusses cholesterol management, dietary choices, and preventing atherosclerosis. His central message is that cardiovascular risk should be assessed using appropriate lipid tests and managed early, with diet and treatment tailored to the individual.

Diet, eggs, and cholesterol absorption

• Dayspring says dietary cholesterol, such as cholesterol from eggs, has little effect on blood cholesterol for most people because much of the cholesterol in the gut comes from the body’s own bile.
• Some people absorb more dietary cholesterol and plant sterols than others. He describes blood levels of plant sterols, including sitosterol and campesterol, as clues that someone may be a “hyperabsorber.”
• He suggests considering dietary cholesterol limits for people confirmed to be significant hyperabsorbers, especially if their ApoB is also elevated. The interview does not give a universal egg limit.
• He cautions that phytosterol supplements may be unsuitable for people with impaired sterol-efflux pathways, since they may absorb and retain excess plant sterols.

Weight loss and dietary approaches

• Dayspring recounts losing weight with a low-carbohydrate, calorie-restricted diet, intermittent fasting, and regular aerobic exercise. He says he would not repeat the particularly demanding five-day fasting regimen he used.
• He favors moderate carbohydrate reduction over strict ketogenic dieting for many people. In his view, strict keto can be difficult to sustain and may sharply worsen lipid markers in some people.
• His broader point is to choose a reasonable eating pattern—such as a vegan or Mediterranean-style diet when appropriate—and check whether it improves the person’s metabolic and lipid markers.
• He emphasizes exercise and not smoking as part of overall risk reduction.

Lipid testing and treatment

• Dayspring strongly emphasizes ApoB as a useful measure of atherogenic particles, alongside standard lipid tests such as LDL cholesterol and non-HDL cholesterol. He argues that elevated ApoB-related measures should not be dismissed.
• Sterol testing may help distinguish high cholesterol synthesis from high absorption and, in selected cases, inform treatment choices.
• He describes treatment options in broad terms:
  • Statins and bempedoic acid reduce cholesterol synthesis.
  • Ezetimibe (Zetia) reduces intestinal cholesterol absorption.
  • Some people may need a combination, with follow-up testing to assess the response.
• He says TMAO testing is not sufficiently supported by clinical-outcome evidence to guide routine care at present.
• For elevated Lp(a), he recommends taking the result seriously and seeking knowledgeable clinical advice. He notes that standard LDL/ApoB-lowering treatment can reduce risk, while PCSK9 inhibitors can lower Lp(a) to some extent. He also discusses investigational Lp(a)-targeting drugs.

Early screening and prevention

• Dayspring advocates early identification of inherited lipid disorders. He says children with a parent known to have familial hypercholesterolemia may need cholesterol testing from around age two; otherwise, he considers ages five to eight a reasonable window for screening.
• He recommends including a one-time Lp(a) test in childhood lipid assessment and says abnormal results should be reviewed with a qualified clinician.
• He frames prevention as a long-term effort: address elevated risk early rather than waiting for signs of established atherosclerosis.
• He also stresses that test results need to be interpreted by someone qualified to act on them. People should seek competent care rather than relying on unsupported online claims.

This is a summary of the interviewee’s views, not individualized medical advice.

Presenters and sources mentioned

• Presenters: John O’Connor (host); Tom Dayspring, MD (guest).
• People, organizations, and works referenced: Peter Attia; David Sinclair; Caldwell Esselstyn; the National Lipid Association; the Family Heart organization; Therapeutic Lipidology; pediatric lipid guidelines; and studies discussed from the New England Journal of Medicine and other observational, randomized, genetic, and autopsy research.